127 related articles for article (PubMed ID: 28166157)
1. 223Ra Dichloride Bone-Targeted Therapy in a Case of Metastatic Salivary Duct Carcinoma.
Manfredi M; Airoldi M; Tucci M; Buttigliero C; Parente A; Angusti T
Clin Nucl Med; 2017 May; 42(5):391-393. PubMed ID: 28166157
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor immunohistochemistry in salivary duct carcinoma: a retrospective study of 188 cases focusing on tumoral heterogeneity and temporal concordance.
Xu B; Dogan S; Haroon Al Rasheed MR; Ghossein R; Katabi N
Hum Pathol; 2019 Nov; 93():30-36. PubMed ID: 31430492
[TBL] [Abstract][Full Text] [Related]
3. Expression pattern of androgen receptor and AR-V7 in androgen-deprivation therapy-naïve salivary duct carcinomas.
Yang RK; Zhao P; Lu C; Luo J; Hu R
Hum Pathol; 2019 Feb; 84():173-182. PubMed ID: 30267779
[TBL] [Abstract][Full Text] [Related]
4. [Bone-specific therapy with radium-223 dichloride : Castration-resistant prostate cancer with symptomatic bone metastases].
Tauber R; Gschwend J; Scheidhauer K; Eiber M; Krönke M
Urologe A; 2017 Jan; 56(1):24-31. PubMed ID: 28058455
[TBL] [Abstract][Full Text] [Related]
5. Radium-223 dichloride in clinical practice: a review.
Florimonte L; Dellavedova L; Maffioli LS
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1896-909. PubMed ID: 27121689
[TBL] [Abstract][Full Text] [Related]
6. Final Outcome of 223Ra-therapy and the Role of 18F-fluoride-PET in Response Evaluation in Metastatic Castration-resistant Prostate Cancer-A Single Institution Experience.
Kairemo K; Milton DR; Etchebehere E; Rohren EM; Macapinlac HA
Curr Radiopharm; 2018; 11(2):147-152. PubMed ID: 29956640
[TBL] [Abstract][Full Text] [Related]
7. Nuclear Medicine Therapy With 223Radium-dichloride for Osseous Metastases in Prostate Carcinoma.
Wale DJ; Viglianti BL; Gross MD; Ferretti A; Rubello D; Wong KK
Am J Clin Oncol; 2019 Jan; 42(1):99-106. PubMed ID: 30204613
[TBL] [Abstract][Full Text] [Related]
8. Salivary Duct Carcinoma: An Update on Morphologic Mimics and Diagnostic Use of Androgen Receptor Immunohistochemistry.
Udager AM; Chiosea SI
Head Neck Pathol; 2017 Sep; 11(3):288-294. PubMed ID: 28321773
[TBL] [Abstract][Full Text] [Related]
9. Bone-seeking radiopharmaceuticals for treatment of osseous metastases, Part 1: α therapy with 223Ra-dichloride.
Pandit-Taskar N; Larson SM; Carrasquillo JA
J Nucl Med; 2014 Feb; 55(2):268-74. PubMed ID: 24343987
[TBL] [Abstract][Full Text] [Related]
10. A Pitfall of the Androgen Deprivation Therapy for Salivary Duct Carcinoma: Hormonal Therapy-Induced Castrate-Resistant Prostate Cancer.
Yajima S; Nakanishi Y; Matsumoto S; Tanabe K; Masuda H
J Maxillofac Oral Surg; 2022 Dec; 21(4):1097-1100. PubMed ID: 36896090
[TBL] [Abstract][Full Text] [Related]
11. 223Ra-dichloride response in a patient with Paget disease and bone metastases secondary to castration-resistant prostate cancer.
García Cañamaque L; Rioja Parada C; García De la Peña P
Tumori; 2017 Nov; 103(Suppl. 1):e53-e55. PubMed ID: 28525684
[TBL] [Abstract][Full Text] [Related]
12. Fatal Intracranial Hemorrhage Due to Thrombocytopenia in a Patient With Castration-Resistant Prostate Cancer Showing Extensive Bone Uptake of Injected 223Ra Dichloride.
Nakahara T; Owaki Y; Kosaka T; Fukada J; Ichimura A; Jinzaki M
Clin Nucl Med; 2018 Jul; 43(7):546-547. PubMed ID: 29742607
[TBL] [Abstract][Full Text] [Related]
13. New treatment option: 223Ra chloride, the first approved unsealed α-emitting radiopharmaceutical.
Colletti PM
Clin Nucl Med; 2013 Sep; 38(9):724-5. PubMed ID: 23867617
[TBL] [Abstract][Full Text] [Related]
14. Radium-223 dichloride therapy in breast cancer with osseous metastases.
Takalkar A; Paryani B; Adams S; Subbiah V
BMJ Case Rep; 2015 Nov; 2015():. PubMed ID: 26581701
[TBL] [Abstract][Full Text] [Related]
15. [Salivary duct carcinoma--a clinicopathological analysis of five cases].
Bień S; Sygut J; Kopczyński J; Postuła S; Ziółkowska M
Otolaryngol Pol; 2007; 61(1):33-8. PubMed ID: 17605416
[TBL] [Abstract][Full Text] [Related]
16. [Bone and calcium metabolism associated with malignancy. Treatment of radium-223 dichloride for bone metastasis in castration resistant prostate cancer patients.].
Uemura H
Clin Calcium; 2018; 28(11):1485-1493. PubMed ID: 30374005
[TBL] [Abstract][Full Text] [Related]
17. FDA approves radiopharmaceutical for metastatic prostate cancer.
Cancer Discov; 2013 Jul; 3(7):OF1. PubMed ID: 23847352
[TBL] [Abstract][Full Text] [Related]
18. Salivary Duct Carcinoma: An Aggressive Salivary Gland Carcinoma with Morphologic Variants, Newly Identified Molecular Characteristics, and Emerging Treatment Modalities.
Rahman M; Griffith CC
Surg Pathol Clin; 2021 Mar; 14(1):111-126. PubMed ID: 33526216
[TBL] [Abstract][Full Text] [Related]
19. Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review.
Uijen MJM; Lassche G; van Engen-van Grunsven ACH; Tada Y; Verhaegh GW; Schalken JA; Driessen CML; van Herpen CML
Cancer Treat Rev; 2020 Sep; 89():102069. PubMed ID: 32717621
[TBL] [Abstract][Full Text] [Related]
20. New radiopharmaceutical agents for the treatment of castration-resistant prostate cancer.
Maffioli L; Florimonte L; Costa DC; Correia Castanheira J; Grana C; Luster M; Bodei L; Chinol M
Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):420-38. PubMed ID: 26222274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
